Children at Massachusetts Boys & Girls Clubs that ran a six-week programme called H2GO! ended the year with a lower BMI z score than children at clubs that did not, according to a cluster randomised trial published in JAMA Network Open on 1 October 2026. The difference was small and only just statistically significant, and … Read more
Within twelve weeks of its approval for weight management, the semaglutide pill was being started almost as often as the injection. A research letter in JAMA Network Open, drawn from the medical records of nearly 48 million US adults who qualified for an obesity drug, counted 148,792 people who began oral semaglutide between 22 December … Read more
UBT251, an experimental once-weekly injection that acts on three hormone receptors, lowered body weight by between 13.6% and 19.7% over 24 weeks, against 2.0% on placebo, in a phase 2 trial of 205 adults in China published in Cell Metabolism on 7 October. It uses the same three-receptor approach as Lilly’s retatrutide. For patients, nothing … Read more
The World Health Organization published its first guidelines on obesity in children and adolescents on 7 October, as two separate documents: one for children up to the age of 9 and one for adolescents aged 10 to 19. Both put structured diet, physical activity and behaviour-change programmes at the centre of care. For children under … Read more
Australian researchers set out to pool the randomised trials of berberine in polyendocrine metabolic ovarian syndrome, or PMOS, the condition previously called polycystic ovary syndrome. Earlier reviews had presented the supplement as a match for metformin. Every eligible trial, four of them covering 452 women, was rated at high risk of compromised integrity, so none … Read more
A chemically synthesised version of semaglutide, developed by the Chinese drugmaker CSPC under the code HD1916, produced weight loss equivalent to Wegovy in a 44-week randomised trial of 462 Chinese adults with obesity, published on 7 October in Diabetes, Obesity and Metabolism. For readers in the US nothing changes yet: HD1916 is not approved here, … Read more
Most adults who stayed on tirzepatide for three years in the SURMOUNT-1 trial put back only a small part of what they had lost after reaching their lowest weight, according to a post hoc analysis published in Obesity Pillars. Of 690 participants with prediabetes who took at least three-quarters of their doses and lost at … Read more
Greenwich Rx, a 503A compounding pharmacy in Tomball, Texas, is recalling ten lots of compounded glutathione injection nationwide because of potentially elevated endotoxin levels. The company says it has received two reports of patients who needed emergency department care after a glutathione product was given intravenously, although the product was not formulated for IV use. … Read more